Predict your next investment

HEALTHCARE | Drug Discovery
mavupharma.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$20M

About Mavupharma

Mavupharma is a drug discovery and development company that is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.

Mavupharma Headquarter Location

5400 Carillon Point Building 5000 4th Floor

Kirkland, Washington, 98003,

United States

Latest Mavupharma News

Inipharm raises $35M to combat liver diseases with a genetics approach

Nov 11, 2020

Nov 11, 2020 8:00am Brian Farmer and his team started Mavupharma, later acquired by AbbVie, to begin work based on promising research, and many of those team members are now a part of Inipharm, “so, in some ways, this team has done this before,” Farmer said. (Courtesy Inipharm) Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing causes, from viruses, to drugs, to alcohol, to genetics. However, many of these diseases share effects, including inflammation and fibrosis, or scarring, of the liver. On the bright side, that means many of these often fatal diseases may be treated someday by mimicking the effects of the same genetic variant that seems to offer protection against severe liver disease. At least, that’s the bet Inipharm is making. The genetic variant in question, HSD17B13, “confers pretty amazing protection against liver disease,” said Inipharm CEO Brian Farmer, citing a 2018 study  published in The New England Journal of Medicine. The study found that this variant reduced the risk of alcoholic liver disease by 42%, for example. And while it doesn't prevent alcohol or misfolded proteins from causing disease, it can keep these diseases from progressing to more serious forms, preventing “inflammation and the fibrosis and the cirrhosis that are what you really worry about,” he said. Seattle- and San Diego-based Inipharm, which debuted with a $35 million series A round, was founded on the promise of this science and on the back of Frazier Healthcare , where Farmer serves as entrepreneur-in-residence. At Frazier, Farmer and his team started Mavupharma , later acquired by AbbVie, to begin work based on this research, and many of those team members are now a part of Inipharm, “so, in some ways, this team has done this before,” Farmer said. SPONSORED BY BIOCLINICA Case Study | Bioclinica Rescues a Study in Jeopardy with a Comprehensive Clinical Adjudication Solution A company was facing major challenges in a global clinical trial program with 30 studies for an uncommon indication. Not only did they need to transition all ongoing clinical trials to the Bioclinica Clinical Adjudication platform for better analysis — but they also needed to do it within 60 days.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mavupharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mavupharma is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mavupharma Patents

Mavupharma has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/13/2018

Application

Application Date

3/13/2018

Grant Date

Title

Related Topics

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.